**INTRODUCTION**

Thank you for submitting an abstract for the 1st European Life After Stroke Forum.

For information and guidance on how to complete this form, please visit (<https://www.safestroke.eu/elasf/>).

The deadline for submitting abstracts is **14 September 2020.**

To submit your abstract please complete all the fields below. Please ensure that you complete all the mandatory fields (\*).

To submit your abstract, please complete this form and send it to info@safestroke.eu

To book a delegate place at the European Life Stroke Forum, please visit (<https://www.safestroke.eu/elasf/>).

To contact SAFE about your abstract, please email info@safestroke.eu

**PRESENTATION TYPE**

|  |  |
| --- | --- |
| Presentation type  | Service |

**YOUR DETAILS**

|  |  |
| --- | --- |
| Title | **Click to choose** |
| First name \* |  |
| Last name \* |  |
| Telephone no. (incl. country code \* |  |
| Email address \* |  |
| Confirm email address \* |  |
| Company/Organisation \* |  |

**ABSTRACT DETAILS**

|  |  |
| --- | --- |
| Preferred presentation type \* | **Click to choose one.** |
| Title \*(No more than 15 words) |  |
| List of author(s) and institutions(s) and email addresses \* |  |
| Presenting author (name and job title) \* |  |
| Funding body \* |  |
| Category \* | **Click to choose one****Please state below if other only:** |

Please structure your submission according to the heading to the side of each text box. The information below must not exceed 230 words. You may submit your information as bullet points. Do not include any tables or graphs.

|  |  |
| --- | --- |
| Summary of the service development \* |  |
| How this is relevant to other countries and what could be the potential impact across countries \* |  |
| How this will improve life after stroke for stroke survivors \* |  |

**SUBMITTING YOUR PROPOSAL**

Please tick the box here to confirm the following: [ ]

1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract **cannot be modified or corrected after final submission**and I am aware that it will be published as submitted.
2. Submission of the abstract constitutes **the consent of all authors** to publication (e.g. conference website, programs, other promotions).
3. The abstract submitter warrants and represents that no part of the information and content provided by him/her (hereafter: the “**Content**“) to SAFE (hereafter: the “**Organisers**“), nor the publication of any such Content by the Organisers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.
4. The abstract submitter grants the organisers a copyright license to reproduce, publish, translate, distribute, and display the text of the content on a royalty-free, perpetual, irrevocable nonexclusive basis.
5. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
6. I understand that the presenting author must be a registered participant.
7. The organisers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.
8. I understand that I must select a specific category for my abstract allocation. Although the abstract review committee will work hard to honour this selection, this cannot be guaranteed. The committee reserves the right to change the category under which the abstract was originally submitted.

**CONFLICTS OF INTEREST**

I declare, that to the best of my knowledge, the only direct or indirect interest I have in both profit and not for profit making organisations potentially related to SAFE are those listed below:

At present or within the last 12 months I have been involved in the following activities (please feel free to add lines as appropriate)

|  |  |  |
| --- | --- | --- |
| Activity | Company | Product(s) or activity |
| Employee |  |  |
| Consultant\* |  |  |
| Principal investigator\*\* |  |  |
| Member of steering committee, advisory board or equivalent body |  |  |
| Investigator (not principal) for the development of a product\*\*\* |  |  |
| Speaker in industry sponsored symposia, press conferences or other meetings |  |  |
| I have received lecture fees and travel expenses (paid to my employer) for lectures at symposia |  |  |

|  |  |
| --- | --- |
| I am a board member in the following national/international society(ies) other than SAFE |  |
| I have financial interest (stocks, shares, patents etc.) in the following profit making organisations potentially related to the SAFE |  |

\* Consultant: expert who charges a fee (personal, institutional or both) for providing advice or services or both

\*\* Principal investigator: investigator responsible for the coordination of investigators at different sites participating in the (multicenter) trial. This includes investigator initiated studies.

\*\*\* Investigator: physician involved in a clinical trial at a specific site. Can be the leader or the member of the clinical trial team. This includes investigator initiated studies.

Date: Place:

Name: Signature: